Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction

Moss, Arthur J.; Zaręba, Wojciech; Hall, William J.; Klein, Helmut U.; Wilber, David J.; Cannom, David S.; Daubert, James P.; Higgins, Steven L.; Brown, Mary W.; Andrews, Mark

doi:10.1056/nejmoa013474

Cited by 6,144 publications

(4,126 citation statements)

References 13 publications

Supporting

Mentioning

3,766

Contrasting

Unclassified

167

Order By: Relevance

“…Although an association of both GDF‐15 and sST2 with sudden cardiac death was previously demonstrated, non‐ischaemic DCM represented one‐third to one‐half of these cohorts 24, 25, 37. Because of different aetiologies of the disease leading to different risks of AD,5, 8 it is of paramount importance to separately investigate ischaemic and non‐ischaemic heart failure patients. In addition, previous studies used sudden cardiac death as an end‐point, which is not always equivalent to fatal ventricular arrhythmia.…”

Section: Discussionmentioning

confidence: 99%

“…Current guidelines for primary prevention with implantable cardioverter defibrillators (ICD) are based on the degree of LV ejection fraction (LVEF ≤ 30%‐40%) reduction 3, 4. However, patients with ischaemic heart disease seem to have more benefit from prophylactic ICD implantation 5, 6, 7. Furthermore, the recently published DANISH trial has demonstrated no mortality benefit from prophylactic ICD implantation in non‐ischaemic DCM 8.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Stojković

Kaider

Koller

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Growth differentiation factor (GDF)‐15 and soluble ST2 (sST2) are established prognostic markers in acute and chronic heart failure. Assessment of these biomarkers might improve arrhythmic risk stratification of patients with non‐ischaemic, dilated cardiomyopathy (DCM) based on left ventricular ejection fraction (LVEF). We studied the prognostic value of GDF‐15 and sST2 for prediction of arrhythmic death (AD) and all‐cause mortality in patients with DCM. We prospectively enrolled 52 patients with DCM and LVEF ≤ 50%. Primary end‐points were time to AD or resuscitated cardiac arrest (RCA), and secondary end‐point was all‐cause mortality. The median follow‐up time was 7 years. A cardiac death was observed in 20 patients, where 10 patients had an AD and 2 patients had a RCA. One patient died a non‐cardiac death. GDF‐15, but not sST2, was associated with increased risk of the AD/RCA with a hazard ratio (HR) of 2.1 (95% CI = 1.1‐4.3; P = .031). GDF‐15 remained an independent predictor of AD/RCA after adjustment for LVEF with adjusted HR of 2.2 (95% CI = 1.1‐4.5; P = .028). Both GDF‐15 and sST2 were independent predictors of all‐cause mortality (adjusted HR = 2.4; 95% CI = 1.4‐4.2; P = .003 vs HR = 1.6; 95% CI = 1.05‐2.7; P = .030). In a model including GDF‐15, sST2, LVEF and NYHA functional class, only GDF‐15 was significantly associated with the secondary end‐point (adjusted HR = 2.2; 95% CI = 1.05‐5.2; P = .038). GDF‐15 is superior to sST2 in prediction of fatal arrhythmic events and all‐cause mortality in DCM. Assessment of GDF‐15 could provide additional information on top of LVEF and help identifying patients at risk of arrhythmic death.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Stojković

Kaider

Koller

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Since then, there have been remarkable technical advances. The ICD is now widely used in high‐risk patients based on evidence from RCTs that supports the use of ICDs for both primary and secondary prevention of SCA 30, 31, 32, 33, 34, 35. In particular, 3 randomized controlled trials evaluated the impact of ICD therapy for secondary prevention indications (Table 1).…”

Section: Randomized Controlled Trials Of Icds and Guidelinesmentioning

confidence: 99%

Implantable Cardioverter‐Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review

Borne

Katz

Betz

et al. 2017

JAHA

View full text Add to dashboard Cite

“…The AVID 110 , CIDS 111 and CASH 112 trials established that ICD improved survival compared with antiarrhythmic agents for secondary prevention of sudden cardiac death (SCD). Other randomised, multicentre studies including MADIT I 19 and II 113 , MUSTT 114 and the SCD‐HeFT 115 , established ICD therapy as effective for primary prevention of SCD in selected patient populations. The LVEF cut offs used in these trials were < 40% in MUSTT, < 35% in MADIT I and SCD‐HeFT and < 30% in MADIT II.…”

Section: Role Of Echocardiography In Therapeutic Interventionmentioning

confidence: 99%

Echocardiographic evaluation of systolic heart failure

Thomas

2009

Australas J Ultrason Med

View full text Add to dashboard Cite

Echocardiography is the most commonly used modality for evaluating left ventricular size and function in the context of systolic heart failure. Traditional techniques, though extensively used, have their limitations and more recently several newer technologies have emerged that are more reproducible, provide prognostic information, guide therapies and have an important role in monitoring progress. This review will evaluate the traditional and more novel techniques used and briefly provide an overview of the role of echocardiography in guiding and monitoring therapies in patients with systolic heart failure.

show abstract

Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction

Abstract: In patients with a prior myocardial infarction and advanced left ventricular dysfunction, prophylactic implantation of a defibrillator improves survival and should be considered as a recommended therapy.

Cited by 6,144 publications

References 13 publications

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

GDF‐15 is a better complimentary marker for risk stratification of arrhythmic death in non‐ischaemic, dilated cardiomyopathy than soluble ST2

Implantable Cardioverter‐Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review

Echocardiographic evaluation of systolic heart failure

Contact Info

Product

Resources

About